Vigil Neuroscience story ‘gaining momentum,’ says Jefferies

After Vigil Neuroscience announced that the FDA has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927 in Alzheimer’s, Jefferies analyst Andrew Tsai called the lift of the hold a fundamental positive as it reassures the Street on ‘3927’s clean safety and enables Vigil to explore higher doses in Phase 1, if needed. The firm, while awaiting ‘3927’s full Phase 1 data in Q1 of 2025, continues to think the Vigil “story is gaining momentum” and keeps a Buy rating and $20 price target on the shares.